Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Randomized Phase 3 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6-methylguanine DNA methyltransferase) Glioblastoma

    Summary
    EudraCT number
    2015-004722-34
    Trial protocol
    DE   AT   BE   ES   GB   SE   NL   PL   FR   DK   IT  
    Global end of trial date
    09 Apr 2024

    Results information
    Results version number
    v1(current)
    This version publication date
    24 Apr 2025
    First version publication date
    24 Apr 2025
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    CA209-548
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    -
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Bristol-Myers Squibb
    Sponsor organisation address
    Chaussée de la Hulpe 185, Brussels, Belgium, 1170
    Public contact
    Global Submission Management, Clinical Trials, Bristol-Myers Squibb International Corporation, mg-gsm-ct@bms.com
    Scientific contact
    Bristol-Myers Squibb Study Director, Bristol-Myers Squibb, mg-gsm-ct@bms.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    09 Apr 2024
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    09 Apr 2024
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The two primary objective of the trial will be OS in the randomized population with no corticosteroids at baseline as well as in the overall randomized population, and PFS determined by BICR, based on RANO criteria
    Protection of trial subjects
    The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonization Good Clinical Practice Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    09 May 2016
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Australia: 26
    Country: Number of subjects enrolled
    Austria: 10
    Country: Number of subjects enrolled
    Belgium: 8
    Country: Number of subjects enrolled
    Canada: 19
    Country: Number of subjects enrolled
    Denmark: 9
    Country: Number of subjects enrolled
    France: 87
    Country: Number of subjects enrolled
    Germany: 71
    Country: Number of subjects enrolled
    Israel: 13
    Country: Number of subjects enrolled
    Italy: 64
    Country: Number of subjects enrolled
    Japan: 59
    Country: Number of subjects enrolled
    Netherlands: 28
    Country: Number of subjects enrolled
    Norway: 6
    Country: Number of subjects enrolled
    Poland: 4
    Country: Number of subjects enrolled
    Russian Federation: 11
    Country: Number of subjects enrolled
    Spain: 27
    Country: Number of subjects enrolled
    Sweden: 7
    Country: Number of subjects enrolled
    Switzerland: 23
    Country: Number of subjects enrolled
    United Kingdom: 16
    Country: Number of subjects enrolled
    United States: 228
    Worldwide total number of subjects
    716
    EEA total number of subjects
    321
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    482
    From 65 to 84 years
    234
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    -

    Pre-assignment
    Screening details
    716 participants were randomized into the study, 709 participants received study treatment

    Period 1
    Period 1 title
    Pre-Treatment
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Single blind [1]
    Roles blinded
    Subject, Investigator

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Radiotherapy, Temozolomide plus Nivolumab
    Arm description
    Radiotherapy: A total dose of 60 Gy [Gray (radiotherapy dose)], in 2 Gy daily fractions on 5 days/week, will be administered in 6 weeks (30 fractions). Nivolumab: 240 mg administered intravenously (IV) as a 30 minute infusion every 2 weeks for 8 doses followed by nivolumab 480 mg as a 30 minute infusion every 4 weeks beginning after 8 doses Temozolomide: 75 mg/m2 orally daily during radiation therapy followed by 4 week break then 6 (28-day) cycles temozolomide on Days 1-5 at 150 mg/m2 in Cycle 1 increasing to 200 mg/m2 as tolerated up to 6 cycles.
    Arm type
    Experimental

    Investigational medicinal product name
    nivolumab
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Intravascular use
    Dosage and administration details
    100mg

    Investigational medicinal product name
    temozolomide
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Capsule
    Routes of administration
    Oral use
    Dosage and administration details
    75mg

    Arm title
    Radiotherapy, Temozolomide plus Placebo
    Arm description
    Radiotherapy: A total dose of 60 Gy [Gray (radiotherapy dose)], in 2 Gy daily fractions on 5 days/week, will be administered in 6 weeks (30 fractions). Placebo: administered intravenously (IV) as a 30 minute infusion every 2 weeks for 8 doses followed by a 30 minute infusion every 4 weeks beginning after 8 doses Temozolomide: 75 mg/m2 orally daily during radiation therapy followed by 4 week break then 6 (28-day) cycles temozolomide on Days 1-5 at 150 mg/m2 in Cycle 1 increasing to 200 mg/m2 as tolerated up to 6 cycles.
    Arm type
    Experimental

    Investigational medicinal product name
    temozolomide
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Capsule
    Routes of administration
    Oral use
    Dosage and administration details
    75mg

    Notes
    [1] - The number of roles blinded appears inconsistent with a single blinded trial. It is expected that there will be one role blinded in a single blind trial.
    Justification: Single blind refers to site blinding, which includes subjects and investigators
    Number of subjects in period 1
    Radiotherapy, Temozolomide plus Nivolumab Radiotherapy, Temozolomide plus Placebo
    Started
    358
    358
    Completed
    354
    355
    Not completed
    4
    3
         Participant withdrew consent
    -
    1
         Not reported
    1
    -
         Participant no longer meets study criteria
    2
    2
         Adverse event unrelated to study drug
    1
    -
    Period 2
    Period 2 title
    End of Treatment
    Is this the baseline period?
    No
    Allocation method
    Randomised - controlled
    Blinding used
    Single blind [2]
    Roles blinded
    Subject, Investigator

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Radiotherapy, Temozolomide plus Nivolumab
    Arm description
    Radiotherapy: A total dose of 60 Gy [Gray (radiotherapy dose)], in 2 Gy daily fractions on 5 days/week, will be administered in 6 weeks (30 fractions). Nivolumab: 240 mg administered intravenously (IV) as a 30 minute infusion every 2 weeks for 8 doses followed by nivolumab 480 mg as a 30 minute infusion every 4 weeks beginning after 8 doses Temozolomide: 75 mg/m2 orally daily during radiation therapy followed by 4 week break then 6 (28-day) cycles temozolomide on Days 1-5 at 150 mg/m2 in Cycle 1 increasing to 200 mg/m2 as tolerated up to 6 cycles.
    Arm type
    Experimental

    Investigational medicinal product name
    temozolomide
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Capsule
    Routes of administration
    Oral use
    Dosage and administration details
    75mg

    Investigational medicinal product name
    nivolumab
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Intravascular use
    Dosage and administration details
    100mg

    Arm title
    Radiotherapy, Temozolomide plus Placebo
    Arm description
    Radiotherapy: A total dose of 60 Gy [Gray (radiotherapy dose)], in 2 Gy daily fractions on 5 days/week, will be administered in 6 weeks (30 fractions). Placebo: administered intravenously (IV) as a 30 minute infusion every 2 weeks for 8 doses followed by a 30 minute infusion every 4 weeks beginning after 8 doses Temozolomide: 75 mg/m2 orally daily during radiation therapy followed by 4 week break then 6 (28-day) cycles temozolomide on Days 1-5 at 150 mg/m2 in Cycle 1 increasing to 200 mg/m2 as tolerated up to 6 cycles.
    Arm type
    Experimental

    Investigational medicinal product name
    temozolomide
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Capsule
    Routes of administration
    Oral use
    Dosage and administration details
    75mg

    Notes
    [2] - The number of roles blinded appears inconsistent with a single blinded trial. It is expected that there will be one role blinded in a single blind trial.
    Justification: Single blind refers to site blinding, which includes subjects and investigators
    Number of subjects in period 2
    Radiotherapy, Temozolomide plus Nivolumab Radiotherapy, Temozolomide plus Placebo
    Started
    355
    354
    Completed
    0
    0
    Not completed
    355
    354
         Adverse event, serious fatal
    2
    1
         Participant withdrew consent
    5
    6
         other reasonse
    21
    10
         poor or non compliant
    -
    1
         Participant no longer meets study criteria
    1
    1
         administrative reason by sponsor
    1
    29
         maximum clinical benefit
    4
    4
         Adverse event unrelated to study drug
    19
    20
         Study Drug Toxicity
    75
    19
         participant request to discontinue treatment
    33
    35
         Lost to follow-up
    1
    2
         Disease Progression
    193
    226

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Radiotherapy, Temozolomide plus Nivolumab
    Reporting group description
    Radiotherapy: A total dose of 60 Gy [Gray (radiotherapy dose)], in 2 Gy daily fractions on 5 days/week, will be administered in 6 weeks (30 fractions). Nivolumab: 240 mg administered intravenously (IV) as a 30 minute infusion every 2 weeks for 8 doses followed by nivolumab 480 mg as a 30 minute infusion every 4 weeks beginning after 8 doses Temozolomide: 75 mg/m2 orally daily during radiation therapy followed by 4 week break then 6 (28-day) cycles temozolomide on Days 1-5 at 150 mg/m2 in Cycle 1 increasing to 200 mg/m2 as tolerated up to 6 cycles.

    Reporting group title
    Radiotherapy, Temozolomide plus Placebo
    Reporting group description
    Radiotherapy: A total dose of 60 Gy [Gray (radiotherapy dose)], in 2 Gy daily fractions on 5 days/week, will be administered in 6 weeks (30 fractions). Placebo: administered intravenously (IV) as a 30 minute infusion every 2 weeks for 8 doses followed by a 30 minute infusion every 4 weeks beginning after 8 doses Temozolomide: 75 mg/m2 orally daily during radiation therapy followed by 4 week break then 6 (28-day) cycles temozolomide on Days 1-5 at 150 mg/m2 in Cycle 1 increasing to 200 mg/m2 as tolerated up to 6 cycles.

    Reporting group values
    Radiotherapy, Temozolomide plus Nivolumab Radiotherapy, Temozolomide plus Placebo Total
    Number of subjects
    358 358 716
    Age categorical
    Units: Subjects
        Adults (18-64 years)
    237 245 482
        From 65-84 years
    121 113 234
    Age Continuous
    Units: Years
        arithmetic mean (standard deviation)
    57.9 ( 12.2 ) 58.7 ( 11.4 ) -
    Sex: Female, Male
    Units: Participants
        Female
    153 161 314
        Male
    205 197 402
    Race/Ethnicity, Customized
    Units: Subjects
        White
    301 318 619
        Black or African American
    4 4 8
        Asian
    35 33 68
        Other
    17 3 20
        Not Reported
    1 0 1
    Ethnicity (NIH/OMB)
    Units: Subjects
        Hispanic or Latino
    7 11 18
        Not Hispanic or Latino
    171 178 349
        Unknown or Not Reported
    180 169 349

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Radiotherapy, Temozolomide plus Nivolumab
    Reporting group description
    Radiotherapy: A total dose of 60 Gy [Gray (radiotherapy dose)], in 2 Gy daily fractions on 5 days/week, will be administered in 6 weeks (30 fractions). Nivolumab: 240 mg administered intravenously (IV) as a 30 minute infusion every 2 weeks for 8 doses followed by nivolumab 480 mg as a 30 minute infusion every 4 weeks beginning after 8 doses Temozolomide: 75 mg/m2 orally daily during radiation therapy followed by 4 week break then 6 (28-day) cycles temozolomide on Days 1-5 at 150 mg/m2 in Cycle 1 increasing to 200 mg/m2 as tolerated up to 6 cycles.

    Reporting group title
    Radiotherapy, Temozolomide plus Placebo
    Reporting group description
    Radiotherapy: A total dose of 60 Gy [Gray (radiotherapy dose)], in 2 Gy daily fractions on 5 days/week, will be administered in 6 weeks (30 fractions). Placebo: administered intravenously (IV) as a 30 minute infusion every 2 weeks for 8 doses followed by a 30 minute infusion every 4 weeks beginning after 8 doses Temozolomide: 75 mg/m2 orally daily during radiation therapy followed by 4 week break then 6 (28-day) cycles temozolomide on Days 1-5 at 150 mg/m2 in Cycle 1 increasing to 200 mg/m2 as tolerated up to 6 cycles.
    Reporting group title
    Radiotherapy, Temozolomide plus Nivolumab
    Reporting group description
    Radiotherapy: A total dose of 60 Gy [Gray (radiotherapy dose)], in 2 Gy daily fractions on 5 days/week, will be administered in 6 weeks (30 fractions). Nivolumab: 240 mg administered intravenously (IV) as a 30 minute infusion every 2 weeks for 8 doses followed by nivolumab 480 mg as a 30 minute infusion every 4 weeks beginning after 8 doses Temozolomide: 75 mg/m2 orally daily during radiation therapy followed by 4 week break then 6 (28-day) cycles temozolomide on Days 1-5 at 150 mg/m2 in Cycle 1 increasing to 200 mg/m2 as tolerated up to 6 cycles.

    Reporting group title
    Radiotherapy, Temozolomide plus Placebo
    Reporting group description
    Radiotherapy: A total dose of 60 Gy [Gray (radiotherapy dose)], in 2 Gy daily fractions on 5 days/week, will be administered in 6 weeks (30 fractions). Placebo: administered intravenously (IV) as a 30 minute infusion every 2 weeks for 8 doses followed by a 30 minute infusion every 4 weeks beginning after 8 doses Temozolomide: 75 mg/m2 orally daily during radiation therapy followed by 4 week break then 6 (28-day) cycles temozolomide on Days 1-5 at 150 mg/m2 in Cycle 1 increasing to 200 mg/m2 as tolerated up to 6 cycles.

    Primary: Progression-free survival (PFS) determined by BICR

    Close Top of page
    End point title
    Progression-free survival (PFS) determined by BICR
    End point description
    The time from randomization to the date of the first documented tumor progression or death by any cause. PFS will be determined by a Blinded Independent Central Review (BICR) assessed based on Radiologic Assessment in Neuro-Oncology (RANO) criteria. Specifically, RANO response criteria indicates that within the first 12 weeks of completion of radiotherapy, progression can only be assessed if the majority of the new enhancement is outside of the radiation field or if there is pathologic confirmation of progressive disease.
    End point type
    Primary
    End point timeframe
    From randomization to the date of the first documented tumor progression or death by any cause. (up to approximately 4.5 years)
    End point values
    Radiotherapy, Temozolomide plus Nivolumab Radiotherapy, Temozolomide plus Placebo
    Number of subjects analysed
    358
    358
    Units: Months
        median (confidence interval 95%)
    9.89 (8.31 to 11.60)
    10.25 (9.46 to 12.09)
    Statistical analysis title
    Statistical Analysis for PFS
    Comparison groups
    Radiotherapy, Temozolomide plus Nivolumab v Radiotherapy, Temozolomide plus Placebo
    Number of subjects included in analysis
    716
    Analysis specification
    Pre-specified
    Analysis type
    Method
    Parameter type
    Cox proportional hazard
    Point estimate
    1.18
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.99
         upper limit
    1.4

    Primary: Overall survival (OS)

    Close Top of page
    End point title
    Overall survival (OS)
    End point description
    The time from the date of randomization to the date of death. who have not died by the end of the study will be censored to last known date alive.
    End point type
    Primary
    End point timeframe
    From randomization to date of death (up to approximately 4.5 years)
    End point values
    Radiotherapy, Temozolomide plus Nivolumab Radiotherapy, Temozolomide plus Placebo
    Number of subjects analysed
    358
    358
    Units: Months
    median (confidence interval 95%)
        Overall Survival
    28.94 (24.57 to 31.64)
    31.84 (28.94 to 33.77)
    Statistical analysis title
    Statistical Analysis for OS
    Statistical analysis description
    All Randomized No Baseline Corticosteroids Participants
    Comparison groups
    Radiotherapy, Temozolomide plus Nivolumab v Radiotherapy, Temozolomide plus Placebo
    Number of subjects included in analysis
    716
    Analysis specification
    Pre-specified
    Analysis type
    Method
    Parameter type
    Cox proportional hazard
    Point estimate
    1.06
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.89
         upper limit
    1.26

    Secondary: Overall Survival (OS) rates at 12 Months

    Close Top of page
    End point title
    Overall Survival (OS) rates at 12 Months
    End point description
    Overall Survival (OS) rate is defined as the percentage of participants surviving at 12 months
    End point type
    Secondary
    End point timeframe
    From randomization to 12 months after first dose
    End point values
    Radiotherapy, Temozolomide plus Nivolumab Radiotherapy, Temozolomide plus Placebo
    Number of subjects analysed
    358
    358
    Units: percentage of participants
        number (confidence interval 95%)
    43.2 (37.6 to 48.7)
    45.7 (40.2 to 51.1)
    No statistical analyses for this end point

    Secondary: Overall Survival (OS) rates at 24 months

    Close Top of page
    End point title
    Overall Survival (OS) rates at 24 months
    End point description
    Overall Survival (OS) rate is defined as the percentage of participants surviving at 24 months
    End point type
    Secondary
    End point timeframe
    From randomization to 24 months after first dose
    End point values
    Radiotherapy, Temozolomide plus Nivolumab Radiotherapy, Temozolomide plus Placebo
    Number of subjects analysed
    358
    358
    Units: percentage of participants
        number (confidence interval 95%)
    17.3 (13.2 to 21.8)
    17.3 (13.3 to 21.8)
    No statistical analyses for this end point

    Secondary: Progression free survival (PFS) based on investigator assessment

    Close Top of page
    End point title
    Progression free survival (PFS) based on investigator assessment
    End point description
    The time from randomization to the date of the first documented tumor progression or death by any cause. PFS will be determined by investigator assessment based Radiologic Assessment in Neuro-Oncology (RANO) criteria. Specifically, RANO response criteria indicates that within the first 12 weeks of completion of radiotherapy, progression can only be assessed if the majority of the new enhancement is outside of the radiation field or if there is pathologic confirmation of progressive disease.
    End point type
    Secondary
    End point timeframe
    From randomization to the date of the first documented tumor progression or death by any cause. (up to approximately 4.5 years)
    End point values
    Radiotherapy, Temozolomide plus Nivolumab Radiotherapy, Temozolomide plus Placebo
    Number of subjects analysed
    358
    358
    Units: Months
        median (confidence interval 95%)
    14.09 (12.62 to 16.56)
    15.18 (13.11 to 17.12)
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Adverse Events and Serious Adverse Events: (From first dose to last dose + 100 days): Approximately 48 Months All-Cause mortality (From randomization to end of study): Approximately up to 52 months
    Adverse event reporting additional description
    The number at Risk for All-Cause Mortality represents all Randomized Participants. The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    27.0
    Reporting groups
    Reporting group title
    Radiotherapy, Temozolomide plus Placebo
    Reporting group description
    Radiotherapy: A total dose of 60 Gy [Gray (radiotherapy dose)], in 2 Gy daily fractions on 5 days/week, will be administered in 6 weeks (30 fractions). Placebo: administered intravenously (IV) as a 30 minute infusion every 2 weeks for 8 doses followed by a 30 minute infusion every 4 weeks beginning after 8 doses Temozolomide: 75 mg/m2 orally daily during radiation therapy followed by 4 week break then 6 (28-day) cycles temozolomide on Days 1-5 at 150 mg/m2 in Cycle 1 increasing to 200 mg/m2 as tolerated up to 6 cycles.

    Reporting group title
    Radiotherapy, Temozolomide plus Nivolumab
    Reporting group description
    Radiotherapy: A total dose of 60 Gy [Gray (radiotherapy dose)], in 2 Gy daily fractions on 5 days/week, will be administered in 6 weeks (30 fractions). Nivolumab: 240 mg administered intravenously (IV) as a 30 minute infusion every 2 weeks for 8 doses followed by nivolumab 480 mg as a 30 minute infusion every 4 weeks beginning after 8 doses Temozolomide: 75 mg/m2 orally daily during radiation therapy followed by 4 week break then 6 (28-day) cycles temozolomide on Days 1-5 at 150 mg/m2 in Cycle 1 increasing to 200 mg/m2 as tolerated up to 6 cycles.

    Serious adverse events
    Radiotherapy, Temozolomide plus Placebo Radiotherapy, Temozolomide plus Nivolumab
    Total subjects affected by serious adverse events
         subjects affected / exposed
    217 / 354 (61.30%)
    259 / 355 (72.96%)
         number of deaths (all causes)
    255
    262
         number of deaths resulting from adverse events
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Non-small cell lung cancer
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Chronic leukaemia
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Glioblastoma
         subjects affected / exposed
    12 / 354 (3.39%)
    7 / 355 (1.97%)
         occurrences causally related to treatment / all
    0 / 12
    0 / 7
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Glioblastoma multiforme
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Malignant melanoma
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Malignant melanoma in situ
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Malignant neoplasm progression
         subjects affected / exposed
    73 / 354 (20.62%)
    75 / 355 (21.13%)
         occurrences causally related to treatment / all
    0 / 75
    0 / 82
         deaths causally related to treatment / all
    0 / 19
    0 / 26
    Metastases to meninges
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Neoplasm
         subjects affected / exposed
    2 / 354 (0.56%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Neoplasm progression
         subjects affected / exposed
    11 / 354 (3.11%)
    6 / 355 (1.69%)
         occurrences causally related to treatment / all
    0 / 12
    0 / 6
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Neoplasm recurrence
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Peritumoural oedema
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Squamous cell carcinoma
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Tumour flare
         subjects affected / exposed
    7 / 354 (1.98%)
    10 / 355 (2.82%)
         occurrences causally related to treatment / all
    8 / 9
    9 / 10
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Tumour pseudoprogression
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Recurrent cancer
         subjects affected / exposed
    0 / 354 (0.00%)
    2 / 355 (0.56%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Vascular disorders
    Orthostatic hypotension
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hypotension
         subjects affected / exposed
    1 / 354 (0.28%)
    2 / 355 (0.56%)
         occurrences causally related to treatment / all
    0 / 1
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Embolism
         subjects affected / exposed
    5 / 354 (1.41%)
    5 / 355 (1.41%)
         occurrences causally related to treatment / all
    1 / 6
    0 / 5
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Deep vein thrombosis
         subjects affected / exposed
    2 / 354 (0.56%)
    2 / 355 (0.56%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Axillary vein thrombosis
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Thrombosis
         subjects affected / exposed
    0 / 354 (0.00%)
    2 / 355 (0.56%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Surgical and medical procedures
    Euthanasia
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Cholecystectomy
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Assisted suicide
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    General disorders and administration site conditions
    Gait disturbance
         subjects affected / exposed
    1 / 354 (0.28%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 1
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Asthenia
         subjects affected / exposed
    3 / 354 (0.85%)
    3 / 355 (0.85%)
         occurrences causally related to treatment / all
    1 / 3
    1 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cyst
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Death
         subjects affected / exposed
    3 / 354 (0.85%)
    4 / 355 (1.13%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 4
         deaths causally related to treatment / all
    0 / 3
    0 / 4
    Drowning
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Fatigue
         subjects affected / exposed
    1 / 354 (0.28%)
    2 / 355 (0.56%)
         occurrences causally related to treatment / all
    0 / 1
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gait inability
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hyperthermia
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Influenza like illness
         subjects affected / exposed
    0 / 354 (0.00%)
    2 / 355 (0.56%)
         occurrences causally related to treatment / all
    0 / 0
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Localised oedema
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Malaise
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Non-cardiac chest pain
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Oedema peripheral
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pyrexia
         subjects affected / exposed
    4 / 354 (1.13%)
    16 / 355 (4.51%)
         occurrences causally related to treatment / all
    2 / 6
    9 / 20
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Sudden death
         subjects affected / exposed
    3 / 354 (0.85%)
    2 / 355 (0.56%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 2
         deaths causally related to treatment / all
    0 / 3
    0 / 2
    Systemic inflammatory response syndrome
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    General physical health deterioration
         subjects affected / exposed
    4 / 354 (1.13%)
    8 / 355 (2.25%)
         occurrences causally related to treatment / all
    1 / 4
    3 / 8
         deaths causally related to treatment / all
    0 / 1
    0 / 2
    Immune system disorders
    Drug hypersensitivity
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hypersensitivity
         subjects affected / exposed
    1 / 354 (0.28%)
    3 / 355 (0.85%)
         occurrences causally related to treatment / all
    1 / 1
    3 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Immunodeficiency
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Reproductive system and breast disorders
    Cystocele
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Benign prostatic hyperplasia
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Pneumonitis
         subjects affected / exposed
    1 / 354 (0.28%)
    3 / 355 (0.85%)
         occurrences causally related to treatment / all
    0 / 2
    3 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Laryngeal obstruction
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hypoxia
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Dyspnoea
         subjects affected / exposed
    3 / 354 (0.85%)
    3 / 355 (0.85%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Acute respiratory failure
         subjects affected / exposed
    1 / 354 (0.28%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 1
    1 / 1
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Pneumothorax
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Lung disorder
         subjects affected / exposed
    0 / 354 (0.00%)
    2 / 355 (0.56%)
         occurrences causally related to treatment / all
    0 / 0
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pulmonary embolism
         subjects affected / exposed
    13 / 354 (3.67%)
    9 / 355 (2.54%)
         occurrences causally related to treatment / all
    0 / 13
    0 / 9
         deaths causally related to treatment / all
    0 / 1
    0 / 3
    Pulmonary oedema
         subjects affected / exposed
    1 / 354 (0.28%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Respiratory disorder
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Respiratory distress
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    1 / 1
    Respiratory failure
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Psychiatric disorders
    Agitation
         subjects affected / exposed
    1 / 354 (0.28%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Confusional state
         subjects affected / exposed
    2 / 354 (0.56%)
    2 / 355 (0.56%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Delirium
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Depression
         subjects affected / exposed
    1 / 354 (0.28%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Mental status changes
         subjects affected / exposed
    0 / 354 (0.00%)
    5 / 355 (1.41%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 5
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Mood altered
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Paranoia
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Suicidal ideation
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Product issues
    Device malfunction
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hepatobiliary disorders
    Hepatitis acute
         subjects affected / exposed
    1 / 354 (0.28%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Autoimmune hepatitis
         subjects affected / exposed
    0 / 354 (0.00%)
    3 / 355 (0.85%)
         occurrences causally related to treatment / all
    0 / 0
    5 / 5
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cholecystitis
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cholelithiasis
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Drug-induced liver injury
         subjects affected / exposed
    1 / 354 (0.28%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 1
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Haemorrhagic hepatic cyst
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hepatic cytolysis
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hepatic function abnormal
         subjects affected / exposed
    0 / 354 (0.00%)
    2 / 355 (0.56%)
         occurrences causally related to treatment / all
    0 / 0
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hepatitis
         subjects affected / exposed
    0 / 354 (0.00%)
    3 / 355 (0.85%)
         occurrences causally related to treatment / all
    0 / 0
    3 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hepatotoxicity
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Liver disorder
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    1 / 1
    Investigations
    Alanine aminotransferase increased
         subjects affected / exposed
    1 / 354 (0.28%)
    3 / 355 (0.85%)
         occurrences causally related to treatment / all
    0 / 1
    3 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Aspartate aminotransferase increased
         subjects affected / exposed
    0 / 354 (0.00%)
    2 / 355 (0.56%)
         occurrences causally related to treatment / all
    0 / 0
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Blood bilirubin increased
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Influenza A virus test positive
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Neutrophil count decreased
         subjects affected / exposed
    1 / 354 (0.28%)
    2 / 355 (0.56%)
         occurrences causally related to treatment / all
    1 / 1
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Platelet count decreased
         subjects affected / exposed
    3 / 354 (0.85%)
    6 / 355 (1.69%)
         occurrences causally related to treatment / all
    3 / 3
    6 / 6
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    White blood cell count decreased
         subjects affected / exposed
    1 / 354 (0.28%)
    4 / 355 (1.13%)
         occurrences causally related to treatment / all
    1 / 1
    4 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    Accidental overdose
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Compression fracture
         subjects affected / exposed
    2 / 354 (0.56%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Fall
         subjects affected / exposed
    2 / 354 (0.56%)
    3 / 355 (0.85%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Femoral neck fracture
         subjects affected / exposed
    1 / 354 (0.28%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Femur fracture
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Foot fracture
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Foreign body
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hip fracture
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Incision site swelling
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Lumbar vertebral fracture
         subjects affected / exposed
    1 / 354 (0.28%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Overdose
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Post procedural complication
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Postoperative wound complication
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Radiation necrosis
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Radiation skin injury
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Spinal compression fracture
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Spinal fracture
         subjects affected / exposed
    2 / 354 (0.56%)
    2 / 355 (0.56%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Subdural haematoma
         subjects affected / exposed
    2 / 354 (0.56%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Traumatic intracranial haemorrhage
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Wound complication
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Wound dehiscence
         subjects affected / exposed
    2 / 354 (0.56%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Toxicity to various agents
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Congenital, familial and genetic disorders
    Branchial cyst
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardiac disorders
    Myocardial infarction
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Acute myocardial infarction
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Angina pectoris
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Atrial fibrillation
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Atrial flutter
         subjects affected / exposed
    0 / 354 (0.00%)
    2 / 355 (0.56%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Atrial tachycardia
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Bundle branch block right
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardiac arrest
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardiac failure
         subjects affected / exposed
    1 / 354 (0.28%)
    2 / 355 (0.56%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Cardiac failure congestive
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Left ventricular failure
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Myocarditis
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Sinus tachycardia
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Stress cardiomyopathy
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Supraventricular tachycardia
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Ventricular tachycardia
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pericarditis
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Nervous system disorders
    Cognitive disorder
         subjects affected / exposed
    6 / 354 (1.69%)
    2 / 355 (0.56%)
         occurrences causally related to treatment / all
    0 / 6
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Acute disseminated encephalomyelitis
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Altered state of consciousness
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Aphasia
         subjects affected / exposed
    5 / 354 (1.41%)
    3 / 355 (0.85%)
         occurrences causally related to treatment / all
    0 / 6
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Brain oedema
         subjects affected / exposed
    7 / 354 (1.98%)
    8 / 355 (2.25%)
         occurrences causally related to treatment / all
    0 / 7
    1 / 8
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Central nervous system lesion
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Central nervous system necrosis
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cerebral cyst
         subjects affected / exposed
    1 / 354 (0.28%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cerebral haemorrhage
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Cerebral infarction
         subjects affected / exposed
    3 / 354 (0.85%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cerebral ischaemia
         subjects affected / exposed
    3 / 354 (0.85%)
    2 / 355 (0.56%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cerebral venous sinus thrombosis
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cerebrospinal fluid leakage
         subjects affected / exposed
    1 / 354 (0.28%)
    3 / 355 (0.85%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cerebrovascular accident
         subjects affected / exposed
    2 / 354 (0.56%)
    4 / 355 (1.13%)
         occurrences causally related to treatment / all
    0 / 2
    1 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Change in seizure presentation
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Dysarthria
         subjects affected / exposed
    0 / 354 (0.00%)
    2 / 355 (0.56%)
         occurrences causally related to treatment / all
    0 / 0
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Drooling
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Epilepsy
         subjects affected / exposed
    12 / 354 (3.39%)
    15 / 355 (4.23%)
         occurrences causally related to treatment / all
    0 / 12
    1 / 22
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Generalised tonic-clonic seizure
         subjects affected / exposed
    1 / 354 (0.28%)
    2 / 355 (0.56%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Haemorrhage intracranial
         subjects affected / exposed
    2 / 354 (0.56%)
    3 / 355 (0.85%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 3
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Headache
         subjects affected / exposed
    6 / 354 (1.69%)
    8 / 355 (2.25%)
         occurrences causally related to treatment / all
    1 / 6
    0 / 10
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hemiparesis
         subjects affected / exposed
    9 / 354 (2.54%)
    7 / 355 (1.97%)
         occurrences causally related to treatment / all
    0 / 10
    0 / 8
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Hemiplegia
         subjects affected / exposed
    0 / 354 (0.00%)
    3 / 355 (0.85%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hydrocephalus
         subjects affected / exposed
    9 / 354 (2.54%)
    10 / 355 (2.82%)
         occurrences causally related to treatment / all
    1 / 10
    0 / 11
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Intracranial pressure increased
         subjects affected / exposed
    3 / 354 (0.85%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Ischaemic stroke
         subjects affected / exposed
    0 / 354 (0.00%)
    2 / 355 (0.56%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Lacunar infarction
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Lethargy
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Muscle contractions involuntary
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Nervous system disorder
         subjects affected / exposed
    2 / 354 (0.56%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Neurological decompensation
         subjects affected / exposed
    2 / 354 (0.56%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Coma
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Depressed level of consciousness
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Dizziness
         subjects affected / exposed
    4 / 354 (1.13%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    1 / 4
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Encephalopathy
         subjects affected / exposed
    5 / 354 (1.41%)
    4 / 355 (1.13%)
         occurrences causally related to treatment / all
    0 / 5
    2 / 5
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Neurological symptom
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Neuropathy peripheral
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Optic neuritis
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Partial seizures
         subjects affected / exposed
    1 / 354 (0.28%)
    2 / 355 (0.56%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Psychomotor skills impaired
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Radiculopathy
         subjects affected / exposed
    0 / 354 (0.00%)
    2 / 355 (0.56%)
         occurrences causally related to treatment / all
    0 / 0
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Seizure
         subjects affected / exposed
    40 / 354 (11.30%)
    48 / 355 (13.52%)
         occurrences causally related to treatment / all
    1 / 53
    5 / 65
         deaths causally related to treatment / all
    0 / 2
    0 / 1
    Simple partial seizures
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Somnolence
         subjects affected / exposed
    1 / 354 (0.28%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Status epilepticus
         subjects affected / exposed
    1 / 354 (0.28%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Subdural hygroma
         subjects affected / exposed
    1 / 354 (0.28%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Syncope
         subjects affected / exposed
    1 / 354 (0.28%)
    2 / 355 (0.56%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Vasogenic cerebral oedema
         subjects affected / exposed
    2 / 354 (0.56%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    0 / 354 (0.00%)
    3 / 355 (0.85%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Autoimmune haemolytic anaemia
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Haemolysis
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Leukopenia
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Lymphopenia
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Microcytic anaemia
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Neutropenia
         subjects affected / exposed
    1 / 354 (0.28%)
    6 / 355 (1.69%)
         occurrences causally related to treatment / all
    1 / 1
    6 / 6
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pancytopenia
         subjects affected / exposed
    2 / 354 (0.56%)
    8 / 355 (2.25%)
         occurrences causally related to treatment / all
    2 / 2
    8 / 8
         deaths causally related to treatment / all
    0 / 0
    1 / 1
    Thrombocytopenia
         subjects affected / exposed
    7 / 354 (1.98%)
    7 / 355 (1.97%)
         occurrences causally related to treatment / all
    6 / 7
    8 / 8
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Febrile neutropenia
         subjects affected / exposed
    2 / 354 (0.56%)
    3 / 355 (0.85%)
         occurrences causally related to treatment / all
    2 / 2
    2 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Ear and labyrinth disorders
    Vertigo
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Eye disorders
    Cataract
         subjects affected / exposed
    1 / 354 (0.28%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Diplopia
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Eye swelling
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Eyelid ptosis
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Iridocyclitis
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Retinal detachment
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Vision blurred
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Abdominal pain upper
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Abdominal pain
         subjects affected / exposed
    1 / 354 (0.28%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Autoimmune colitis
         subjects affected / exposed
    0 / 354 (0.00%)
    2 / 355 (0.56%)
         occurrences causally related to treatment / all
    0 / 0
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Constipation
         subjects affected / exposed
    1 / 354 (0.28%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Diarrhoea
         subjects affected / exposed
    1 / 354 (0.28%)
    4 / 355 (1.13%)
         occurrences causally related to treatment / all
    0 / 2
    4 / 5
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Diverticular perforation
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Dysphagia
         subjects affected / exposed
    1 / 354 (0.28%)
    2 / 355 (0.56%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Enterocolitis
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastritis
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastritis haemorrhagic
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal haemorrhage
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Intestinal obstruction
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    2 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Large intestinal obstruction
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Nausea
         subjects affected / exposed
    1 / 354 (0.28%)
    4 / 355 (1.13%)
         occurrences causally related to treatment / all
    1 / 1
    3 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Oesophagitis
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Vomiting
         subjects affected / exposed
    3 / 354 (0.85%)
    2 / 355 (0.56%)
         occurrences causally related to treatment / all
    3 / 3
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Colitis
         subjects affected / exposed
    0 / 354 (0.00%)
    5 / 355 (1.41%)
         occurrences causally related to treatment / all
    0 / 0
    5 / 5
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Skin and subcutaneous tissue disorders
    Stevens-Johnson syndrome
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Skin reaction
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Rash
         subjects affected / exposed
    2 / 354 (0.56%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    2 / 2
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Rash maculo-papular
         subjects affected / exposed
    2 / 354 (0.56%)
    2 / 355 (0.56%)
         occurrences causally related to treatment / all
    2 / 2
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Scar pain
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Drug eruption
         subjects affected / exposed
    0 / 354 (0.00%)
    2 / 355 (0.56%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Drug reaction with eosinophilia and systemic symptoms
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Renal and urinary disorders
    Nephrolithiasis
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Urinary retention
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Tubulointerstitial nephritis
         subjects affected / exposed
    0 / 354 (0.00%)
    2 / 355 (0.56%)
         occurrences causally related to treatment / all
    0 / 0
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Renal failure
         subjects affected / exposed
    0 / 354 (0.00%)
    2 / 355 (0.56%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Nephropathy
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Acute kidney injury
         subjects affected / exposed
    2 / 354 (0.56%)
    4 / 355 (1.13%)
         occurrences causally related to treatment / all
    2 / 2
    1 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Bladder stenosis
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Haematuria
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Nephritis
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Endocrine disorders
    Adrenal insufficiency
         subjects affected / exposed
    2 / 354 (0.56%)
    2 / 355 (0.56%)
         occurrences causally related to treatment / all
    0 / 2
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Diabetes insipidus
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hypothyroidism
         subjects affected / exposed
    0 / 354 (0.00%)
    3 / 355 (0.85%)
         occurrences causally related to treatment / all
    0 / 0
    3 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Ankylosing spondylitis
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Arthritis
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Autoimmune myositis
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Back pain
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Eosinophilic fasciitis
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Intervertebral disc protrusion
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Mobility decreased
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Muscular weakness
         subjects affected / exposed
    3 / 354 (0.85%)
    3 / 355 (0.85%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Osteoarthritis
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Arthralgia
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infections and infestations
    Meningitis aseptic
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Abscess limb
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Appendicitis
         subjects affected / exposed
    2 / 354 (0.56%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Bacterial infection
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    COVID-19
         subjects affected / exposed
    1 / 354 (0.28%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cellulitis
         subjects affected / exposed
    1 / 354 (0.28%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 1
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cystitis
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Device related infection
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Diverticulitis
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Encephalitis
         subjects affected / exposed
    2 / 354 (0.56%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 2
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal infection
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Herpes simplex
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Herpes zoster
         subjects affected / exposed
    1 / 354 (0.28%)
    5 / 355 (1.41%)
         occurrences causally related to treatment / all
    0 / 1
    2 / 5
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Influenza
         subjects affected / exposed
    2 / 354 (0.56%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Intervertebral discitis
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Meningitis
         subjects affected / exposed
    1 / 354 (0.28%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Meningitis viral
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Wound infection
         subjects affected / exposed
    1 / 354 (0.28%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pneumocystis jirovecii pneumonia
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    1 / 1
    Pneumonia
         subjects affected / exposed
    5 / 354 (1.41%)
    14 / 355 (3.94%)
         occurrences causally related to treatment / all
    0 / 5
    3 / 17
         deaths causally related to treatment / all
    0 / 1
    0 / 4
    Pneumonia aspiration
         subjects affected / exposed
    1 / 354 (0.28%)
    4 / 355 (1.13%)
         occurrences causally related to treatment / all
    0 / 1
    1 / 5
         deaths causally related to treatment / all
    0 / 1
    1 / 2
    Pneumonia viral
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Post procedural infection
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Postoperative wound infection
         subjects affected / exposed
    2 / 354 (0.56%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pulmonary sepsis
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Pyometra
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory tract infection
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Rhinitis
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Sepsis
         subjects affected / exposed
    1 / 354 (0.28%)
    4 / 355 (1.13%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Septic shock
         subjects affected / exposed
    0 / 354 (0.00%)
    2 / 355 (0.56%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Sinusitis
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Staphylococcal bacteraemia
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Upper respiratory tract infection
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Urinary tract infection
         subjects affected / exposed
    4 / 354 (1.13%)
    7 / 355 (1.97%)
         occurrences causally related to treatment / all
    0 / 4
    1 / 7
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Urosepsis
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Parotitis
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    Hyponatraemia
         subjects affected / exposed
    1 / 354 (0.28%)
    2 / 355 (0.56%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Adult failure to thrive
         subjects affected / exposed
    1 / 354 (0.28%)
    0 / 355 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Decreased appetite
         subjects affected / exposed
    1 / 354 (0.28%)
    2 / 355 (0.56%)
         occurrences causally related to treatment / all
    0 / 1
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Dehydration
         subjects affected / exposed
    4 / 354 (1.13%)
    3 / 355 (0.85%)
         occurrences causally related to treatment / all
    0 / 4
    1 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Diabetes mellitus
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Failure to thrive
         subjects affected / exposed
    0 / 354 (0.00%)
    1 / 355 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Hyperglycaemia
         subjects affected / exposed
    1 / 354 (0.28%)
    2 / 355 (0.56%)
         occurrences causally related to treatment / all
    0 / 1
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Radiotherapy, Temozolomide plus Placebo Radiotherapy, Temozolomide plus Nivolumab
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    343 / 354 (96.89%)
    351 / 355 (98.87%)
    Vascular disorders
    Hypertension
         subjects affected / exposed
    32 / 354 (9.04%)
    29 / 355 (8.17%)
         occurrences all number
    47
    36
    General disorders and administration site conditions
    Fatigue
         subjects affected / exposed
    176 / 354 (49.72%)
    186 / 355 (52.39%)
         occurrences all number
    223
    250
    Asthenia
         subjects affected / exposed
    40 / 354 (11.30%)
    42 / 355 (11.83%)
         occurrences all number
    52
    50
    Chills
         subjects affected / exposed
    13 / 354 (3.67%)
    25 / 355 (7.04%)
         occurrences all number
    15
    32
    Gait disturbance
         subjects affected / exposed
    34 / 354 (9.60%)
    29 / 355 (8.17%)
         occurrences all number
    38
    29
    Malaise
         subjects affected / exposed
    18 / 354 (5.08%)
    17 / 355 (4.79%)
         occurrences all number
    21
    19
    Oedema peripheral
         subjects affected / exposed
    28 / 354 (7.91%)
    30 / 355 (8.45%)
         occurrences all number
    34
    36
    Pain
         subjects affected / exposed
    9 / 354 (2.54%)
    18 / 355 (5.07%)
         occurrences all number
    9
    19
    Pyrexia
         subjects affected / exposed
    31 / 354 (8.76%)
    70 / 355 (19.72%)
         occurrences all number
    37
    114
    Respiratory, thoracic and mediastinal disorders
    Cough
         subjects affected / exposed
    51 / 354 (14.41%)
    59 / 355 (16.62%)
         occurrences all number
    63
    70
    Dyspnoea
         subjects affected / exposed
    20 / 354 (5.65%)
    27 / 355 (7.61%)
         occurrences all number
    21
    29
    Psychiatric disorders
    Anxiety
         subjects affected / exposed
    34 / 354 (9.60%)
    32 / 355 (9.01%)
         occurrences all number
    36
    32
    Confusional state
         subjects affected / exposed
    21 / 354 (5.93%)
    20 / 355 (5.63%)
         occurrences all number
    21
    24
    Depression
         subjects affected / exposed
    34 / 354 (9.60%)
    30 / 355 (8.45%)
         occurrences all number
    35
    32
    Insomnia
         subjects affected / exposed
    47 / 354 (13.28%)
    54 / 355 (15.21%)
         occurrences all number
    52
    63
    Investigations
    Alanine aminotransferase increased
         subjects affected / exposed
    39 / 354 (11.02%)
    63 / 355 (17.75%)
         occurrences all number
    52
    81
    Aspartate aminotransferase increased
         subjects affected / exposed
    16 / 354 (4.52%)
    46 / 355 (12.96%)
         occurrences all number
    22
    57
    Blood creatinine increased
         subjects affected / exposed
    14 / 354 (3.95%)
    23 / 355 (6.48%)
         occurrences all number
    20
    30
    Lymphocyte count decreased
         subjects affected / exposed
    62 / 354 (17.51%)
    67 / 355 (18.87%)
         occurrences all number
    129
    170
    Neutrophil count decreased
         subjects affected / exposed
    40 / 354 (11.30%)
    34 / 355 (9.58%)
         occurrences all number
    74
    79
    Platelet count decreased
         subjects affected / exposed
    75 / 354 (21.19%)
    75 / 355 (21.13%)
         occurrences all number
    131
    127
    Weight decreased
         subjects affected / exposed
    33 / 354 (9.32%)
    50 / 355 (14.08%)
         occurrences all number
    36
    57
    Weight increased
         subjects affected / exposed
    21 / 354 (5.93%)
    13 / 355 (3.66%)
         occurrences all number
    24
    15
    White blood cell count decreased
         subjects affected / exposed
    44 / 354 (12.43%)
    40 / 355 (11.27%)
         occurrences all number
    78
    105
    Injury, poisoning and procedural complications
    Fall
         subjects affected / exposed
    46 / 354 (12.99%)
    37 / 355 (10.42%)
         occurrences all number
    64
    51
    Radiation skin injury
         subjects affected / exposed
    38 / 354 (10.73%)
    35 / 355 (9.86%)
         occurrences all number
    39
    36
    Nervous system disorders
    Cognitive disorder
         subjects affected / exposed
    19 / 354 (5.37%)
    19 / 355 (5.35%)
         occurrences all number
    19
    20
    Dizziness
         subjects affected / exposed
    53 / 354 (14.97%)
    47 / 355 (13.24%)
         occurrences all number
    61
    50
    Dysgeusia
         subjects affected / exposed
    27 / 354 (7.63%)
    36 / 355 (10.14%)
         occurrences all number
    28
    39
    Headache
         subjects affected / exposed
    135 / 354 (38.14%)
    142 / 355 (40.00%)
         occurrences all number
    192
    220
    Hemiparesis
         subjects affected / exposed
    25 / 354 (7.06%)
    23 / 355 (6.48%)
         occurrences all number
    27
    24
    Memory impairment
         subjects affected / exposed
    36 / 354 (10.17%)
    26 / 355 (7.32%)
         occurrences all number
    37
    28
    Paraesthesia
         subjects affected / exposed
    23 / 354 (6.50%)
    26 / 355 (7.32%)
         occurrences all number
    28
    30
    Seizure
         subjects affected / exposed
    76 / 354 (21.47%)
    63 / 355 (17.75%)
         occurrences all number
    112
    82
    Tremor
         subjects affected / exposed
    26 / 354 (7.34%)
    22 / 355 (6.20%)
         occurrences all number
    30
    26
    Aphasia
         subjects affected / exposed
    32 / 354 (9.04%)
    30 / 355 (8.45%)
         occurrences all number
    39
    31
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    26 / 354 (7.34%)
    42 / 355 (11.83%)
         occurrences all number
    32
    64
    Lymphopenia
         subjects affected / exposed
    39 / 354 (11.02%)
    43 / 355 (12.11%)
         occurrences all number
    56
    63
    Neutropenia
         subjects affected / exposed
    32 / 354 (9.04%)
    33 / 355 (9.30%)
         occurrences all number
    60
    51
    Thrombocytopenia
         subjects affected / exposed
    67 / 354 (18.93%)
    69 / 355 (19.44%)
         occurrences all number
    89
    110
    Leukopenia
         subjects affected / exposed
    30 / 354 (8.47%)
    20 / 355 (5.63%)
         occurrences all number
    36
    29
    Eye disorders
    Dry eye
         subjects affected / exposed
    15 / 354 (4.24%)
    18 / 355 (5.07%)
         occurrences all number
    15
    18
    Vision blurred
         subjects affected / exposed
    23 / 354 (6.50%)
    30 / 355 (8.45%)
         occurrences all number
    23
    31
    Gastrointestinal disorders
    Abdominal pain
         subjects affected / exposed
    27 / 354 (7.63%)
    32 / 355 (9.01%)
         occurrences all number
    33
    36
    Constipation
         subjects affected / exposed
    145 / 354 (40.96%)
    163 / 355 (45.92%)
         occurrences all number
    215
    221
    Diarrhoea
         subjects affected / exposed
    72 / 354 (20.34%)
    77 / 355 (21.69%)
         occurrences all number
    98
    108
    Nausea
         subjects affected / exposed
    159 / 354 (44.92%)
    187 / 355 (52.68%)
         occurrences all number
    247
    265
    Stomatitis
         subjects affected / exposed
    9 / 354 (2.54%)
    25 / 355 (7.04%)
         occurrences all number
    9
    30
    Vomiting
         subjects affected / exposed
    75 / 354 (21.19%)
    90 / 355 (25.35%)
         occurrences all number
    99
    135
    Skin and subcutaneous tissue disorders
    Alopecia
         subjects affected / exposed
    109 / 354 (30.79%)
    115 / 355 (32.39%)
         occurrences all number
    111
    119
    Dry skin
         subjects affected / exposed
    27 / 354 (7.63%)
    24 / 355 (6.76%)
         occurrences all number
    31
    25
    Erythema
         subjects affected / exposed
    22 / 354 (6.21%)
    29 / 355 (8.17%)
         occurrences all number
    25
    30
    Pruritus
         subjects affected / exposed
    77 / 354 (21.75%)
    86 / 355 (24.23%)
         occurrences all number
    92
    113
    Rash
         subjects affected / exposed
    58 / 354 (16.38%)
    85 / 355 (23.94%)
         occurrences all number
    70
    105
    Rash maculo-papular
         subjects affected / exposed
    13 / 354 (3.67%)
    32 / 355 (9.01%)
         occurrences all number
    18
    45
    Renal and urinary disorders
    Pollakiuria
         subjects affected / exposed
    13 / 354 (3.67%)
    18 / 355 (5.07%)
         occurrences all number
    13
    19
    Endocrine disorders
    Hypothyroidism
         subjects affected / exposed
    9 / 354 (2.54%)
    28 / 355 (7.89%)
         occurrences all number
    9
    30
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    53 / 354 (14.97%)
    61 / 355 (17.18%)
         occurrences all number
    72
    71
    Back pain
         subjects affected / exposed
    34 / 354 (9.60%)
    41 / 355 (11.55%)
         occurrences all number
    42
    47
    Muscular weakness
         subjects affected / exposed
    28 / 354 (7.91%)
    35 / 355 (9.86%)
         occurrences all number
    29
    37
    Myalgia
         subjects affected / exposed
    15 / 354 (4.24%)
    30 / 355 (8.45%)
         occurrences all number
    18
    37
    Pain in extremity
         subjects affected / exposed
    16 / 354 (4.52%)
    28 / 355 (7.89%)
         occurrences all number
    20
    34
    Infections and infestations
    Conjunctivitis
         subjects affected / exposed
    12 / 354 (3.39%)
    20 / 355 (5.63%)
         occurrences all number
    12
    22
    Nasopharyngitis
         subjects affected / exposed
    31 / 354 (8.76%)
    37 / 355 (10.42%)
         occurrences all number
    45
    51
    Oral candidiasis
         subjects affected / exposed
    12 / 354 (3.39%)
    20 / 355 (5.63%)
         occurrences all number
    13
    24
    Upper respiratory tract infection
         subjects affected / exposed
    19 / 354 (5.37%)
    21 / 355 (5.92%)
         occurrences all number
    25
    26
    Urinary tract infection
         subjects affected / exposed
    34 / 354 (9.60%)
    45 / 355 (12.68%)
         occurrences all number
    38
    59
    Metabolism and nutrition disorders
    Decreased appetite
         subjects affected / exposed
    87 / 354 (24.58%)
    97 / 355 (27.32%)
         occurrences all number
    104
    115
    Hyperglycaemia
         subjects affected / exposed
    34 / 354 (9.60%)
    25 / 355 (7.04%)
         occurrences all number
    54
    34
    Hypokalaemia
         subjects affected / exposed
    15 / 354 (4.24%)
    34 / 355 (9.58%)
         occurrences all number
    20
    49

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    22 Apr 2016
    The main purpose of the first global amendment is to provide additional clarification on several items in response to questions arising from investigators and IRB/IEC/HAs:
    26 Oct 2016
    This amendment updates the nivolumab clinical information in GBM and safety management algorithms as a result of most recent version of the Investigator Brochure (version 15). The amendment also clarifies several items as well as corrects minor errors.  Safety data from protocol CA209-143 added to the nivolumab clinical information in GBM.  Renal, Pulmonary, Hepatic, and Skin safety management algorithms revised based on IBv.15  Time windows and technical descriptions around assessments and administration schedule have been added or expanded to allow for flexibility at the site level while not affecting the conduct or the analysis of the data.
    03 Jun 2017
    Changed to a Phase 3 trial with Primary Objective of OS
    17 Jun 2017
    Corrects an error in the Dose Delay Criteria and aligns the Dose Delay Criteria and Dose Discontinuation Criteria with the nivolumab program standards.
    08 Nov 2018
    Major Changes  Progression Free Survival is now a primary objective of the study, changed from secondary.  Overall survival (OS) rate at 12 and 24 months and PFS based on investigator assessment by RANO criteria are added as secondary objectives.  The evaluation of tumor mutational burden (TMB) with efficacy endpoints is now an exploratory objective, changed from secondary.  Blinded Independent Central Review (BICR) of study images has been added to the study.  The statistical section has been revised to support changes in the study objectives. The study will now include 1 formal interim analysis for PFS and 1 formal interim analysis for OS for superiority.
    26 Feb 2021
    The Data Monitoring Committee (DMC) determined that there was no possibility for the study to have a positive overall survival (OS) result, and recommended to unblind the sites and subjects, which was approved by BMS. The study was officially unblinded on 22-Dec-2020. As a consequence, the timing of the primary OS analysis, originally planned for when 337 and 494 events were to be reached respectively for the population without corticosteroids at baseline and the overall population, has been updated. To prevent any bias due to unblinding of subjects, the primary OS analysis will be conducted using the unblinding date of 22-Dec-2020. Study procedures for subjects remaining on treatment and in safety follow-up have been simplified, and OS follow-up after unblinding has been removed. Protocol language per BMS standards for nivolumab studies and for COVID-19 has been incorporated.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 08 07:40:28 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA